46 completed, 8 terminated, 6 unknown, 1 active not recruiting. 63 Phase 3, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 63 | Completed 46, Terminated 8, Unknown 6, Active not recruiting 1, Not yet recruiting 1, Withdrawn 1 |
| Phase 2 | 5 | Completed 2, Active not recruiting 1, Terminated 1, Unknown 1 |
Follow Overactive Bladder: new trials by email Literature Review of Overactive Bladder trials Research Report on Overactive Bladder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy of Gabapentin Combined With Solifenacin for Non-neurogenic Overactive Bladder in Women solifenacin combined with gabapentin, solifenacin monotherapy - Overactive Bladder | Phase 3 | Not yet recruiting | Mansoura University | 60 | 2026-02-01 | 2026-02-24 |
| Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder Symptoms OnabotulinumtoxinA - Urinary Incontinence, Overactive Bladder Syndrome | Phase 2 / Phase 3 | Active not recruiting | Northwestern University | 66 | 2023-07-13 | 2026-11-06 |
| The Effect of Local Anesthetic Solution in the Bladder Prior to Botox Injections in the Bladder Alkalinized Lidocaine, Placebo Sodium Chloride 0.9% Inj - Urge Incontinence, Overactive Bladder | Phase 3 | Unknown | Herlev and Gentofte Hospital | 50 | 2022-09-12 | 2022-09-22 |
| A Study to Evaluate the Efficacy and Safety of DA-8010 in Patients With Overactive Bladder DA-8010 Placebo, DA-8010 2.5mg, DA-8010 5mg - Overactive Bladder | Phase 3 | Completed | Dong-A ST Co., Ltd. | 607 | 2022-05-12 | 2024-06-26 |
| To Evaluate the Efficacy and Safety of JLP-2002 on Symptoms of Overactive Bladder JLP-2002 A mg, Placebo - Overactive Bladder | Phase 3 | Completed | Jeil Pharmaceutical Co., Ltd. | 210 | 2020-05-21 | 2022-01-28 |
| Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia Vibegron - Overactive Bladder | Phase 3 | Completed | Urovant Sciences GmbH | 276 | 2019-09-19 | 2024-08-21 |
| Clinical Trial to Evaluate the Efficacy and Safety of MEDITOXIN® in Subject With Idiopathic Overactive Bladder Neuronox, Placebo - Overactive Bladder | Phase 3 | Unknown | Medy-Tox | 216 | 2019-08-23 | 2020-07-28 |
| Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) Vibegron, Placebo - Overactive Bladder | Phase 3 | Completed | Urovant Sciences GmbH | 1105 | 2019-03-26 | 2024-08-07 |
| An Extension Study to Examine the Safety and Tolerability of a New Drug in Patients With Symptoms of Overactive Bladder (OAB). Vibegron, placebos, Tolterodine Tartrate ER - Overactive Bladder | Phase 3 | Completed | Urovant Sciences GmbH | 506 | 2018-06-14 | 2021-03-18 |
| A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB) vibegron, Vibegron placebo, Tolterodine Tartrate ER - Overactive Bladder | Phase 3 | Completed | Urovant Sciences GmbH | 1530 | 2018-03-26 | 2021-03-04 |
| Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease solifenacin, Pelvic floor muscle exercise-based behavioral therapy - Overactive Bladder, Parkinson Disease | Phase 3 | Completed | VA Office of Research and Development | 77 | 2018-03-01 | 2024-09-24 |
| Low-level Light Therapy for Overactive Bladder and Urinary Incontinence Low-level light therapy, Placebo - Overactive Bladder, Urinary Incontinence | Phase 3 | Unknown | Seoul National University Hospital | 120 | 2016-12-01 | 2016-12-07 |
| Efficacy and Safety Evaluating Study to Compare Uritos® (Imidafenacin) and Urotol® (Tolterodine) for Treatment of Overactive Bladder. Uritos®, Urotol® - Overactive Bladder | Phase 3 | Completed | R-Pharm | 300 | 2016-07-18 | 2019-05-21 |
| Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 2 Botulinum toxin type A, Placebo - Urinary Incontinence, Overactive Bladder | Phase 3 | Terminated | Ipsen | 258 | 2016-07-08 | 2022-09-28 |
| Solifenacin Succinate for Treatment of Urinary Toxicity Occurring During Radiotherapy of Prostatic Cancer Succinate of Solifenacin, Placebo of Succinate of Solifenacin - Overactive Bladder | Phase 3 | Terminated | Center Eugene Marquis | 4 | 2016-07-01 | 2018-01-19 |
| Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1 Botulinum toxin type A, Placebo - Urinary Incontinence, Overactive Bladder | Phase 3 | Terminated | Ipsen | 227 | 2016-03-01 | 2022-09-28 |
| A Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type A in Patients With Overactive Bladder (OAB) Botulinum Toxin Type A for Injection, Placebo - Overactive Bladder | Phase 3 | Unknown | Lanzhou Institute of Biological Products Co., Ltd | 216 | 2016-03-01 | 2018-01-03 |
| Extension Study of Fesoterodine for Overactive Bladder Syndrome in Children. Fesoterodine - Overactive Bladder | Phase 3 | Completed | Stéphane Bolduc | 26 | 2015-10-01 | 2019-07-30 |
| Clinical Study to Assess the Efficacy and Safety of THVD-201 in Patients With OAB THVD-201, Placebo(For THVD-201), Detrusitol 2mg tablet - Overactive Bladder | Phase 3 | Completed | SK Chemicals Co., Ltd. | 384 | 2015-01-01 | 2017-01-12 |
| Fesoterodine and Oxybutynin XL for Overactive Bladder Syndrome in Children Fesoterodine, Oxybutynin XL - Overactive Bladder | Phase 3 | Completed | Stéphane Bolduc | 62 | 2014-12-01 | 2019-07-30 |
Showing 20 of 63. Sign in to see all of them.
Urinary Bladder, Overactive (63) · Urinary Incontinence (17) · Urinary Incontinence, Urge (11) · Lower Urinary Tract Symptoms (4) · Nocturia (3) · Urologic Diseases (3) · Prostatic Hyperplasia (2) · Hematuria (1) · Hereditary Sensory and Autonomic Neuropathies (1) · Male Urogenital Diseases (1) · Pain, Procedural (1) · Parkinson Disease (1) · Spinal Cord Injuries (1) · Syndrome (1) · Urinary Tract Infections (1)
Female Urogenital Diseases (63) · Female Urogenital Diseases and Pregnancy Complications (63) · Pathological Conditions, Signs and Symptoms (63) · Signs and Symptoms (63) · Urinary Bladder Diseases (63) · Urogenital Diseases (63) · Urological Manifestations (63) · Male Urogenital Diseases (62) · Urologic Diseases (60) · Lower Urinary Tract Symptoms (59) · Urination Disorders (26) · Urinary Incontinence (9) · Central Nervous System Diseases (2) · Genital Diseases (2) · Genital Diseases, Male (2)
Botulinum Toxins, Type A (18) · Tolterodine Tartrate (11) · Solifenacin Succinate (8) · Saline Solution (7) · fesoterodine (7) · N-(4-((5-(hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)phenyl)-4-oxo-4,6,7,8-tetrahydropyrrolo(1,2-a)pyrimidine-6-carboxamide (4) · mirabegron (4) · oxybutynin (4) · imidafenacin (3) · abobotulinumtoxinA (2) · propiverine (2) · ritobegron ethyl (2) · Behavior Therapy (1) · DA-8010 (1) · Dimethyl Sulfoxide (1)
Allergan (8) · Pfizer (6) · Urovant Sciences GmbH (4) · Astellas Pharma Europe B.V. (2) · CHU de Quebec-Universite Laval (2) · Duramed Research (2) · Ipsen (2) · Kissei Pharmaceutical Co., Ltd. (2) · Ono Pharmaceutical Co., Ltd. (2) · Stéphane Bolduc (2) · APOGEPHA Arzneimittel GmbH (1) · Astellas Pharma Inc (1) · Bayer (1) · Boston Scientific Corporation (1) · Center Eugene Marquis (1)
United States (36) · Canada (16) · Poland (14) · South Korea (12) · Belgium (11) · Germany (11) · Czechia (10) · Russia (10) · United Kingdom (9) · Spain (8) · Ukraine (8) · Italy (7) · Australia (6) · France (6) · Hungary (6)
Yasuhiro Omori (2) · Alexis Te (1) · Amy Krambeck, MD (1) · Anthony Visco, MD (1) · Benjamin Li, PhD (1) · Christopher P. Smith, MD (1) · Daniela Marschall-Kehrel, MD (1) · Elizabeth Camille Vaughan, MD MS (1) · Frank F. Tu, MD, MPH (1)
PMID 37160401, PMID 35881009, PMID 24754838, PMID 25288099, PMID 26231052, PMID 35400537, PMID 37811598, PMID 18502028, PMID 18584946, PMID 19143854, PMID 19233423, PMID 19348029, PMID 20121659, PMID 20723260, PMID 21428726, PMID 21798658, PMID 22008247, PMID 22092152, PMID 22503020, PMID 22965657, PMID 23036134, PMID 23218404, PMID 23448285, PMID 23608668, PMID 23892704, PMID 26516810, PMID 26876327, PMID 27564385, PMID 29866467, PMID 31930360, PMID 32665528, PMID 33332699, PMID 33356445, PMID 33469832, PMID 33620895, PMID 34921665, PMID 35685566, PMID 36384907, PMID 37586052, PMID 37586057, PMID 38651909, PMID 39797697, PMID 40658410, PMID 41363221
2015 (2), 2017 (2), 2018 (2), 2014 (1), U01HD041249 (1), U10HD041250 (1), U10HD041261 (1), U10HD041267 (1), U10HD054136 (1), U10HD054214 (1), U10HD054215 (1), U10HD054241 (1)